JPH0475888B2 - - Google Patents

Info

Publication number: JPH0475888B2
Authority: JP; Japan
Prior art keywords: enteric; substance; substances; capsules; intestinal
Prior art date: 1986-03-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

JP7367886A

Other languages

English (en)

Japanese (ja)

Other versions

JPS62230714A (ja

Inventor

Toshimitsu Yoshioka

Hiroshi Inoe

Mieko Amaya

Tsuneo Kato

Tetsuo Nakamura

Seiichiro Igarashi

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Snow Brand Milk Products Co Ltd

Original Assignee

Snow Brand Milk Products Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-03-31

Filing date

1986-03-31

Publication date

1992-12-02

1986-03-31 Application filed by Snow Brand Milk Products Co Ltd filed Critical Snow Brand Milk Products Co Ltd

1986-03-31 Priority to JP61073678A priority Critical patent/JPS62230714A/ja

1987-10-09 Publication of JPS62230714A publication Critical patent/JPS62230714A/ja

1992-12-02 Publication of JPH0475888B2 publication Critical patent/JPH0475888B2/ja

Status Granted legal-status Critical Current

Links

239000000126 substance Substances 0.000 claims description 39
239000002775 capsule Substances 0.000 claims description 31
230000000968 intestinal effect Effects 0.000 claims description 17
210000000936 intestine Anatomy 0.000 claims description 15
239000007788 liquid Substances 0.000 claims description 15
241000186000 Bifidobacterium Species 0.000 claims description 12
230000036760 body temperature Effects 0.000 claims description 10
238000002844 melting Methods 0.000 claims description 10
230000008018 melting Effects 0.000 claims description 10
239000013543 active substance Substances 0.000 claims description 6
239000012907 medicinal substance Substances 0.000 claims 1
239000003921 oil Substances 0.000 description 22
235000019198 oils Nutrition 0.000 description 22
210000004051 gastric juice Anatomy 0.000 description 12
238000000034 method Methods 0.000 description 12
239000011162 core material Substances 0.000 description 11
239000000463 material Substances 0.000 description 8
241000894006 Bacteria Species 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 6
239000011248 coating agent Substances 0.000 description 6
238000000576 coating method Methods 0.000 description 6
239000012530 fluid Substances 0.000 description 6
239000012528 membrane Substances 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 5
230000001580 bacterial effect Effects 0.000 description 5
230000000694 effects Effects 0.000 description 5
238000005538 encapsulation Methods 0.000 description 5
229940088598 enzyme Drugs 0.000 description 5
239000003925 fat Substances 0.000 description 5
239000002245 particle Substances 0.000 description 5
238000001035 drying Methods 0.000 description 4
230000001681 protective effect Effects 0.000 description 4
210000002784 stomach Anatomy 0.000 description 4
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
229960001138 acetylsalicylic acid Drugs 0.000 description 3
238000001816 cooling Methods 0.000 description 3
244000005700 microbiome Species 0.000 description 3
239000007921 spray Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
240000004668 Valerianella locusta Species 0.000 description 2
235000003560 Valerianella locusta Nutrition 0.000 description 2
230000002411 adverse Effects 0.000 description 2
230000001112 coagulating effect Effects 0.000 description 2
230000006378 damage Effects 0.000 description 2
239000008187 granular material Substances 0.000 description 2
239000002609 medium Chemical group 0.000 description 2
239000000203 mixture Substances 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
239000001263 FEMA 3042 Substances 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
102000004882 Lipase Human genes 0.000 description 1
108090001060 Lipase Proteins 0.000 description 1
239000004367 Lipase Substances 0.000 description 1
235000019482 Palm oil Nutrition 0.000 description 1
102000019280 Pancreatic lipases Human genes 0.000 description 1
108050006759 Pancreatic lipases Proteins 0.000 description 1
108010019160 Pancreatin Proteins 0.000 description 1
LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
239000001888 Peptone Substances 0.000 description 1
108010080698 Peptones Proteins 0.000 description 1
239000005062 Polybutadiene Substances 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
229920007962 Styrene Methyl Methacrylate Polymers 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000000507 anthelmentic effect Effects 0.000 description 1
229940124339 anthelmintic agent Drugs 0.000 description 1
239000000921 anthelmintic agent Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
-1 atebrin Chemical compound 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008602 contraction Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
229960002001 ethionamide Drugs 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
239000007789 gas Substances 0.000 description 1
210000004211 gastric acid Anatomy 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
208000014674 injury Diseases 0.000 description 1
229940040461 lipase Drugs 0.000 description 1
235000019421 lipase Nutrition 0.000 description 1
239000006402 liver broth Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229920003145 methacrylic acid copolymer Polymers 0.000 description 1
229940117841 methacrylic acid copolymer Drugs 0.000 description 1
ADFPJHOAARPYLP-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;styrene Chemical compound COC(=O)C(C)=C.C=CC1=CC=CC=C1 ADFPJHOAARPYLP-UHFFFAOYSA-N 0.000 description 1
IQSHMXAZFHORGY-UHFFFAOYSA-N methyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound COC(=O)C=C.CC(=C)C(O)=O IQSHMXAZFHORGY-UHFFFAOYSA-N 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
235000014593 oils and fats Nutrition 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000002540 palm oil Substances 0.000 description 1
229940116369 pancreatic lipase Drugs 0.000 description 1
229940055695 pancreatin Drugs 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
235000019319 peptone Nutrition 0.000 description 1
229920002857 polybutadiene Polymers 0.000 description 1
239000005518 polymer electrolyte Substances 0.000 description 1
239000002861 polymer material Substances 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
239000011253 protective coating Substances 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
238000005507 spraying Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
229940033123 tannic acid Drugs 0.000 description 1
235000015523 tannic acid Nutrition 0.000 description 1
229920002258 tannic acid Polymers 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1

Landscapes

Medicinal Preparation (AREA)

JP61073678A 1986-03-31 1986-03-31 腸溶性カプセル Granted JPS62230714A (ja)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP61073678A JPS62230714A (ja)	1986-03-31	1986-03-31	腸溶性カプセル

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP61073678A JPS62230714A (ja)	1986-03-31	1986-03-31	腸溶性カプセル

Publications (2)

Publication Number	Publication Date
JPS62230714A JPS62230714A (ja)	1987-10-09
JPH0475888B2 true JPH0475888B2 (cs)	1992-12-02

Family

ID=13525123

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP61073678A Granted JPS62230714A (ja)	1986-03-31	1986-03-31	腸溶性カプセル

Country Status (1)

Country	Link
JP (1)	JPS62230714A (cs)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6632429B1 (en)	1999-12-17	2003-10-14	Joan M. Fallon	Methods for treating pervasive development disorders
US20070053895A1 (en)	2000-08-14	2007-03-08	Fallon Joan M	Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en)	2000-11-16	2011-10-04	Curemark Llc	Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
FR2863828B1 (fr) *	2003-12-23	2007-02-02	Gervais Danone Sa	Produit alimentaire liquide comprenant des granules de bacteries lactiques
US20080058282A1 (en)	2005-08-30	2008-03-06	Fallon Joan M	Use of lactulose in the treatment of autism
US8658163B2 (en)	2008-03-13	2014-02-25	Curemark Llc	Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en)	2008-04-18	2011-12-27	Curemark Llc	Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en)	2008-06-26	2016-04-26	Curemark Llc	Methods and compositions for the treatment of symptoms of Williams Syndrome
ES2732453T3 (es)	2008-07-01	2019-11-22	Curemark Llc	Métodos y composiciones para el tratamiento de síntomas de trastornos neurológicos y de salud mental
US10776453B2 (en)	2008-08-04	2020-09-15	Galenagen, Llc	Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en)	2008-10-03	2010-04-15	Fallon Joan M	Methods and compositions for the treatment of symptoms of prion diseases
JP2012514604A (ja)	2009-01-06	2012-06-28	キュレロンリミテッドライアビリティカンパニー	大腸菌（Ｅ．ｃｏｌｉ）による経口感染の治療または予防のための組成物および方法
CA3050530A1 (en)	2009-01-06	2010-07-15	Galenagen, Llc	Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
US9056050B2 (en)	2009-04-13	2015-06-16	Curemark Llc	Enzyme delivery systems and methods of preparation and use
US9511125B2 (en)	2009-10-21	2016-12-06	Curemark Llc	Methods and compositions for the treatment of influenza
MX362974B (es)	2011-04-21	2019-02-28	Curemark Llc	Compuestos para el tratamiento de alteraciones neuropsiquiatricas.
US10350278B2 (en)	2012-05-30	2019-07-16	Curemark, Llc	Methods of treating Celiac disease
AU2018250823A1 (en)	2017-04-10	2019-10-17	Curemark, Llc	Compositions for treating addiction
JP2021114952A (ja) *	2020-01-28	2021-08-10	ナットリオミックス, インコーポレイテッドNutriomix, Inc.	腸溶性組成物、該腸溶性組成物を含む飲食品、該腸溶性組成物の崩壊時間を制御する方法、及び該腸溶性組成物の製造方法
US11541009B2 (en)	2020-09-10	2023-01-03	Curemark, Llc	Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

1986
- 1986-03-31 JP JP61073678A patent/JPS62230714A/ja active Granted

Also Published As

Publication number	Publication date
JPS62230714A (ja)	1987-10-09

Publication	Publication Date	Title
JPS62230714A (ja)	1987-10-09	腸溶性カプセル
EP0693963B1 (fr)	1997-03-26	Utilisation d'une reaction de transacylation entre un polysaccharide esterifie et une polyamine pour former en milieu aqueux une membrane au moins en surface de particules gelifiees, particules ainsi realisees, procedes et compositions en contenant
DE69505374T2 (de)	1999-05-12	In überzogenen mikrogranulaten enthaltene, stabilisierte biologisch aktive verbindungen, die in lebensmittelflüssigkeiten suspendiert werden können
EP0239361B1 (en)	1992-12-02	Sustained-release pharmaceutical preparation
Ouyang et al.	2004	Artificial cell microcapsule for oral delivery of live bacterial cells for therapy: design, preparation, and in-vitro characterization
FI112600B (fi)	2003-12-31	Tuetulla nestekalvolla varustettuja antovälineitä
CN104321052B (zh)	2016-08-17	在大肠中特异性崩解的胶囊
JPH03505448A (ja)	1991-11-28	遅延放出性製剤
CA2076983A1 (en)	1991-10-12	Taste masking of ibuprofen by fluid bed coating
JPS6111933B2 (cs)	1986-04-05
AU2003274229A1 (en)	2004-03-03	Galenic formulation for colon targeted delivery of active ingredients
AU2021101350A4 (en)	2021-05-13	Oral mscs liquid-filled capsule for treating inflammatory bowel diseases and other intestinal diseases
JPH0441434A (ja)	1992-02-12	腸溶性コーティングを施した乳酸菌錠剤
JP2006510731A (ja)	2006-03-30	標的化送達
CN113440497B (zh)	2022-10-11	在胃酸中稳定的微囊粉及制备方法和应用
EP1042405A1 (en)	2000-10-11	Gelatine compositions
EP1063976A1 (en)	2001-01-03	Tarch capsules containing microorganisms and/or polypeptides or proteins and a process for producing them
WO1997000674A1 (en)	1997-01-09	A method of preparing an oral preparation provided on the outer side with an enteric coating, as well as an oral preparation obtained by the method
JPH0482827A (ja)	1992-03-16	腸溶性カプセル
CN109497555A (zh)	2019-03-22	一种槐糖微胶囊及其制备方法和应用
US3557279A (en)	1971-01-19	Microencapsulation form of an anti-inflammatory drug
JPH0568446B2 (cs)	1993-09-29
IE56604B1 (en)	1991-10-09	Pinacidil-containing preparations
WO1999052512A1 (en)	1999-10-21	Coated starch capsules and a process for producing them
JPH04364123A (ja)	1992-12-16	被覆用素材及びそれを用いた腸溶性造粒物